아미코젠

092040KOSDAQ기타 식품 제조업

38.6 / 100

Reference Date: 2026-06-10

Financial Score5.0 / 40

News Sentiment20.6 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 23.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Amicozen is an industrial biotech company specializing in developing enzymes for antibiotic production and health care materials using its proprietary gene evolution technology. Key products include N-acetylglucosamine, phytin, and collagen peptides, with expansion into endolysin enzyme business through collaboration with Lysando AG since 2020.

Number of Employees

228people

Average Salary

49.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 13.214.0Point

PBR

0.96Industry Average 0.561.0Point

1.7x industry avg (risky)

ROE

-27.74Industry Average 2.720.0Point

Well below industry avg

Debt Ratio

57.69Industry Average 11.910.0Point

4.8x industry avg (risky)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼33.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼293.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -22.7% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 82.5

Positive
아미코젠, 1분기 순이익 194억…흑자전환
아미코젠이 흑자 전환을 달성하며 분기 실적이 크게 개선되었다.
Positive
아미코젠, 오송첨단의료산업진흥재단과 '바이오소부장 국산화' 협력
아미코젠이 오송첨단의료산업진흥재단과 협력하여 바이오소부장 국산화를 추진함으로써 기술 혁신과 시장 경쟁력 강화가 기대된다.
Positive
KBIOHealth-아미코젠, 세포주 개발 등 바이오의약품 소부장 발...
아미코젠과 KBIOHealth 간의 바이오소부장 분야 협력 강화로 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 1,309Won52-week high 4,24052-week low 1,175

1-month return0.0Point

1m -23.23% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-14